Locatelli, F. Et Al. 2024. Ruxolitinib in treatment-naive or corticosteroid-refractory paediatric patients with chronic graft-versus-host disease (REACH5): interim analysis of a single-arm, multicentre, phase 2 study. The Lancet Haematology , vol.11, no.8 .

Locatelli, F., Antmen, B., Kang, H. J., Koh, K., Takahashi, Y., Kupesiz, A., ... Dias Matos, M. G. A.(2024). Ruxolitinib in treatment-naive or corticosteroid-refractory paediatric patients with chronic graft-versus-host disease (REACH5): interim analysis of a single-arm, multicentre, phase 2 study. The Lancet Haematology , vol.11, no.8.

Locatelli, Franco Et Al. "Ruxolitinib in treatment-naive or corticosteroid-refractory paediatric patients with chronic graft-versus-host disease (REACH5): interim analysis of a single-arm, multicentre, phase 2 study," The Lancet Haematology , vol.11, no.8, 2024

Locatelli, Franco Et Al. "Ruxolitinib in treatment-naive or corticosteroid-refractory paediatric patients with chronic graft-versus-host disease (REACH5): interim analysis of a single-arm, multicentre, phase 2 study." The Lancet Haematology , vol.11, no.8, 2024

Locatelli, F. Et Al. (2024) . "Ruxolitinib in treatment-naive or corticosteroid-refractory paediatric patients with chronic graft-versus-host disease (REACH5): interim analysis of a single-arm, multicentre, phase 2 study." The Lancet Haematology , vol.11, no.8.

@article{article, author={Franco Locatelli Et Al. }, title={Ruxolitinib in treatment-naive or corticosteroid-refractory paediatric patients with chronic graft-versus-host disease (REACH5): interim analysis of a single-arm, multicentre, phase 2 study}, journal={The Lancet Haematology}, year=2024}